Clinical Trials Logo

Phase Two clinical trials

View clinical trials related to Phase Two.

Filter by:
  • None
  • Page 1

NCT ID: NCT03936452 Completed - Radiotherapy Clinical Trials

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Start date: April 28, 2019
Phase: Phase 2
Study type: Interventional

This study aims to investigate the treatment of previously untreated stage I-II Extranodal NK/T Cell Lymphoma with sintilimab, peg-aspargase and anlotinib, "sandwich" with radiotherapy. The primary endpoint is the complete response rate (CRR) at the end of the treatment, and the second endpoints are CRR after two cycles of the combined regimen (CRR2), overall response rate (ORR) at the end of the treatment, survival time (OS and PFS) and toxicities.